A Phase 1 interventional study of WCK 5222 and IV placebo matched to WCK 5222 / Moxifloxacin IV solution in QT/QTc Interval in Healthy Volunteers, sponsored by Wockhardt. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-13.
Sponsored by Wockhardt · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A Randomized, Double-Blind, Double-Dummy, Placebo- and Positive-Controlled, Crossover Study to Evaluate the Effect of WCK 5222 on the QT/QTc Interval in Healthy Volunteers
Wockhardt is the lead sponsor of 39 studies on the registry; 3 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 1 (11%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
WCK 5222 IV solution administered as either a 30- or 60-minute IV infusion)
Drug: WCK 5222 · Drug: IV placebo matched to WCK 5222 / Moxifloxacin IV solution
placebo capsule matched to moxifloxacin overencapsulated tablet IV placebo matched to WCK 5222 IV solution
Drug: IV placebo matched to WCK 5222 / Moxifloxacin IV solution
positive control
Drug: IV placebo matched to WCK 5222 / Moxifloxacin IV solution · Drug: Moxifloxacin 400-mg
FEP-ZID IV solution administered as either a 30- or 60-minute IV infusion)
Placebo (IV placebo matched to FEP-ZID IV solution) and 1 placebo capsule matched to moxifloxacin overencapsulated tablet
Also known as: Placebo capsule matched to moxifloxacin
Moxifloxacin 400-mg positive control (overencapsulated tablet)
Incidence of delay in cardiac repolarization induced by WCK 5222
as shown by analysis of the QT interval.
Time frame: 0-4 days
Incidence of adverse events to assess tolerability at the supratherapeutic dose to be used in the thorough QT evaluation
Tolerability will be assessed by review of number of AEs
Time frame: 0-4 days
Incidence of AEs to assess the safety of high doses of single-dose administration of FEP-ZID
Safety will be assessed by review of adverse events (AEs), ECGs, and clinical laboratory safety test results
Time frame: 0-4 days
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2017 to primary completion in Jun 2017, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cefepime-zidebactam